{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+or+Refractory+Solid+Tumors&page=2", "query": { "condition": "Recurrent or Refractory Solid Tumors", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+or+Refractory+Solid+Tumors&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T04:54:05.300Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02095132", "title": "Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Central Nervous System Embryonal Tumor With Rhabdoid Features", "Central Nervous System Embryonal Tumor, Not Otherwise Specified", "Central Nervous System Ganglioneuroblastoma", "Embryonal Tumor With Multilayered Rosettes, C19MC-Altered", "Pineoblastoma", "Primary Central Nervous System Neoplasm", "Recurrent Childhood Central Nervous System Embryonal Neoplasm", "Recurrent Malignant Solid Neoplasm", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Rhabdomyosarcoma", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Rhabdomyosarcoma" ], "interventions": [ { "name": "Adavosertib", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 76, "start_date": "2014-03-28", "completion_date": "2023-06-30", "has_results": true, "last_update_posted_date": "2023-09-26", "last_synced_at": "2026-05-22T04:54:05.300Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02095132" }, { "nct_id": "NCT02574728", "title": "Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "30 Years", "sex": "ALL", "summary": "12 Months to 30 Years" }, "enrollment_count": 46, "start_date": "2015-06", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-05-22T04:54:05.300Z", "location_count": 6, "location_summary": "Phoenix, Arizona • Wilmington, Delaware • Atlanta, Georgia + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02574728" }, { "nct_id": "NCT02595866", "title": "Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AIDS-Related Non-Hodgkin Lymphoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Hepatocellular Carcinoma", "HIV Infection", "Kaposi Sarcoma", "Locally Advanced Lung Non-Small Cell Carcinoma", "Locally Advanced Malignant Solid Neoplasm", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Non-Hodgkin Lymphoma", "Recurrent Classic Hodgkin Lymphoma", "Recurrent Malignant Neoplasm", "Refractory Classic Hodgkin Lymphoma", "Refractory Malignant Neoplasm", "Stage III Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Unresectable Melanoma" ], "interventions": [ { "name": "Antiretroviral Therapy", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2016-04-04", "completion_date": "2024-03-25", "has_results": true, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-05-22T04:54:05.300Z", "location_count": 12, "location_summary": "Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02595866" }, { "nct_id": "NCT00003107", "title": "Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Gestational Trophoblastic Tumor", "Kidney Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Neuroblastoma", "Ovarian Cancer", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "recombinant interleukin-12", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1997-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-09-10", "last_synced_at": "2026-05-22T04:54:05.300Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003107" }, { "nct_id": "NCT00544284", "title": "Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Lymphoma", "Metastatic Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2005-01", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2013-02-15", "last_synced_at": "2026-05-22T04:54:05.300Z", "location_count": 2, "location_summary": "Duarte, California • Pasadena, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00544284" }, { "nct_id": "NCT00003555", "title": "Paclitaxel Plus Chemoprotection With Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "amifostine trihydrate", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "State University of New York - Upstate Medical University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "1998-07", "completion_date": "2003-05", "has_results": false, "last_update_posted_date": "2013-06-26", "last_synced_at": "2026-05-22T04:54:05.300Z", "location_count": 1, "location_summary": "Syracuse, New York", "locations": [ { "city": "Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003555" }, { "nct_id": "NCT00060645", "title": "Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumors", "Lymphoma", "Multiple Myeloma" ], "interventions": [ { "name": "ridaforolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2003-05", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2015-08-27", "last_synced_at": "2026-05-22T04:54:05.300Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060645" }, { "nct_id": "NCT04870944", "title": "CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Midline Glioma, H3 K27-Altered", "Metastatic Malignant Neoplasm in the Central Nervous System", "Recurrent Diffuse Intrinsic Pontine Glioma", "Recurrent Diffuse Midline Glioma, H3 K27-Altered", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Primary Malignant Central Nervous System Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Primary Malignant Central Nervous System Neoplasm" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspirate", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "FACT Complex-targeting Curaxin CBL0137", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 63, "start_date": "2022-01-28", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-05-22T04:54:05.300Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04870944" }, { "nct_id": "NCT04985604", "title": "Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Solid Tumor", "CRAF Gene Amplification", "RAF1 Gene Amplification", "BRAF Gene Fusion", "BRAF Fusion", "CRAF Gene Fusion", "CRAF Fusion", "RAF1 Gene Fusion", "RAF1 Fusion", "Thyroid Cancer, Papillary", "Spitzoid Melanoma", "Pilocytic Astrocytoma", "Pilocytic Astrocytoma, Adult", "Non Small Cell Lung Cancer", "Non-Small Cell Adenocarcinoma", "Colorectal Cancer", "Pancreatic Acinar Carcinoma", "Spitzoid Malignant Melanoma", "Bladder Cancer", "Bladder Urothelial Carcinoma", "MAP Kinase Family Gene Mutation", "RAF Mutation" ], "interventions": [ { "name": "Tovorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Day One Biopharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 23, "start_date": "2021-07-15", "completion_date": "2024-07-08", "has_results": true, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-05-22T04:54:05.300Z", "location_count": 8, "location_summary": "Los Angeles, California • Newport Beach, California • Aurora, Colorado + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04985604" }, { "nct_id": "NCT05130255", "title": "GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "SCLC", "Malignant Melanoma", "Sarcoma", "High Risk Neuroblastoma" ], "interventions": [ { "name": "GD2-SADA:177Lu-DOTA Complex", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Y-mAbs Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 60, "start_date": "2022-11-17", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2024-10-02", "last_synced_at": "2026-05-22T04:54:05.300Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Duarte, California • Chicago, Illinois + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05130255" } ] }